Chronic pulmonary thrombepigen(CPT)



👉 miRNAs for the diagnostic of chronic thromboembolic pulmonary hypertension.

CLINICAL NEED / NEED

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of a pulmonary embolism (PE), characterized by thromboembolic material inside pulmonary arteries that causes an increase in the pulmonary vascular resistance, heart failure and even death. Currently, **there is not effective biomarkers** for an early diagnostic and the correct identification can take among 14 and 24 months, with a late starting of the treatment.

SOLUTION

Our group has identified a **new panel of miARNs** that allows a **non-invasive diagnostic** of CTPEH, and also distinguish between patients with PE or CTPEH or even the prognosis of PE.

COMPETITIVE ADVANTAGE

Nowadays, there is **no precise and specific diagnosis** for CTEPH **nor distinction among PE and CTEPH.** Moreover, the diagnostic test presented allows a **prognosis of PE**.

INTELLECTUAL PROPERTY

PCT patent (PCT/ES2023/070761) application was submitted 19 of December 2023. FRCB-IDIBAPS, HCB, SAS and IIS La Fe share joint ownership.

DEVELOPMENT

The **Proof of Concept** has been achieved and the team is working to achieve **TRL4**: validation



LOOKING FOR...

Partners for **license agreement** or a **co-development.**

THE TEAM

Dr *Joan Albert Barbera*

Dra Olga Tura

Dra Remedios Otero

Dra Veronica Sanchez Lopez

Dra Pilar Medina

Dra Julia Oto

CONTACT DETAILS

Knowledge and Technology Transfer Office

innova@recerca.clinic.cat

September 2023